Staining of human DR5 transfected cells with Anti-Human CD262 (DR5) PE. Appropriate isotype controls were used (open histogram). Total viable cells were used for analysis.
Contents: Anti-Human CD262 (DR5) Biotin Catalog Number: 13-9908 Concentration: 0.5 mg/ml Formulation: aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer Storage Conditions: Store at 2-8°C. Do not freeze. Clone: DJR2-4 (a.k.a. 7-8) Host/Isotype: Mouse IgG1, κ
Product Options
Cat. No.
Size
Price
Add Qty to Cart
13-9908-80
25 ug
13-9908-82
100 ug
Note: Several countries will continue to be supplied via distributors. Country specific prices may apply.
Flow Cytometry Product Notes: Test Sizes: To accommodate multicolor flow cytometry, eBioscience is in the process of reducing test size volumes from 20 µL to 5 µL. Please check your antibody vial for the recommended test size. Fluorochrome Replacements: eBioscience is in the process of replacing all Alexa Fluor® 647 conjugated products with eFluor® 660 conjugated products.
Description
The DJR2-4 monoclonal antibody reacts with human DR5, also known as TRAIL-R2, Apo2, TRICK2 and KILLER. DR5 binds to TRAIL, activates NF-κB, and induces TRAIL-mediated apoptosis. DR5 is expressed broadly by normal tissues as well as several tumor cells.
Applications Reported
The DJR2-4 (a.k.a. 7-8) antibody has been reported for use in flow cytometric analysis.
Applications Tested
The DJR2-4 (a.k.a. 7-8) antibody has been tested by flow cytometric analysis of human MOLT-4 cell line and human DR5-transfected cells. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 105 to 108 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
References
Earel JK Jr, Vanoosten RL, Griffith TS. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 2006 Jan 1;66(1):499-507. (FC, PubMed)